26557-78-8

Basic information

• Product Name: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)
• Synonyms: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl);4-(prop-2-ynyloxy)aniline;4-Aminophenyl propargyl ether;4-(2-Propynyloxy)aniline;4-(2-Propyn-1-yloxy)benzenamine;4-Prop-2-ynyloxy-phenylamine;[4-(Prop-2-yn-1-yloxy)phenyl]amine hydrochloride
• CAS NO: 26557-78-8
• Molecular Formula: C₉H₉NO
• Molecular Weight: 183.64
• Mol File: 26557-78-8.mol

Chemical Properties

• Melting Point: 52.0 to 56.0 °C
• Boiling Point: 95°C/10mmHg(lit.)
• Flash Point: >110℃
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.90±0.10(Predicted)
• CAS DataBase Reference: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)(26557-78-8)
• EPA Substance Registry System: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)(26557-78-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 26557-78-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl) is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Polymer Science:
In the field of polymer science, 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl) is used as a monomer or a building block for the creation of novel polymers with specific properties. Its incorporation into polymer structures can lead to materials with enhanced characteristics, such as improved strength, flexibility, or chemical resistance.
Used in Material Science:
4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl) is utilized as a component in the development of advanced materials with tailored properties. Its presence in these materials can contribute to improved performance in areas such as electronics, coatings, or adhesives, depending on the desired application.

Upstream product

• 54840-15-2 4-N-tert-butoxycarbonylaminophenol 
• 106-96-7 propargyl bromide 
• 54840-30-1 tert-butyl (4-(prop-2-yn-1-yloxy)phenyl)-carbamate 
• 123-30-8 4-amino-phenol 
• 26257-98-7 4-[2-(4-hydroxyphenyl)diazenyl]benzoic acid methyl ester 
• 103-90-2 4-acetaminophenol 
• 100-02-7 4-nitro-phenol 
• 17061-85-7 1-nitro-4-(prop-2-ynyloxy)benzene 
• 1693-39-6 N-(4-hydroxyphenyl)formamide 
• 26557-77-7 N-(4-(prop-2-yn-1-yloxy)phenyl)acetamide 

Downstream Products

• 51857-69-3 ((E)-3,7-Dimethyl-octa-2,6-dienyl)-(4-prop-2-ynyloxy-phenyl)-amine 
• 51857-70-6 Bis-((E)-3,7-dimethyl-octa-2,6-dienyl)-(4-prop-2-ynyloxy-phenyl)-amine 
• 76663-11-1 2-(4-Prop-2-ynyloxy-phenylamino)-N-(4-sulfamoyl-phenyl)-acetamide 
• 1561107-36-5 4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)aniline 
• 1561106-96-4 4-hydroxy-5-methyl-3-((4-(prop-2-ynyloxy)phenyl)diazenyl)-2H-pyran-2-one 
• 1561107-09-2 3-((4-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-4-hydroxy-5-methyl-2H-pyran-2-one 
• 1561107-15-0 6-((4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-17-2 6-((4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-20-7 6-((4-((1-(4-tolyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-benzo[d][1,3]dioxol-5-ol 
• 1561107-22-9 6-((4-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-25-2 6-((4-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-28-5 6-((4-((1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-31-0 6-((4-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561106-99-7 4-hydroxy-3-((4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-5-methyl-2H-pyran-2-one 

Relevant articles and documents

Divinylsulfonamides as Specific Linkers for Stapling Disulfide Bonds in Peptides

A new class of N-phenyl-divinylsulfonamides which can be easily prepared have been successfully developed and utilized as efficient linkers in the field of disulfide bond modification. Functional divinylsulfonamides provide opportunities for the specific

Divinylsulfonamides enable the construction of homogeneous antibody–drug conjugates

Methods that site-specifically attach payloads to an antibody with controlled DAR (Drug-Antibody Ratio) are highly desirable for the generation of homogeneous antibody-drug conjugates (ADCs). We describe the use of N-phenyl-divinylsulfonamide scaffold as

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

Azoacetylenes for the Synthesis of Arylazotriazole Photoswitches

We report a modular approach toward novel arylazotriazole photoswitches and their photophysical characterization. Addition of lithiated TIPS-acetylene to aryldiazonium tetrafluoroborate salts gives a wide range of azoacetylenes, constituting an underexplored class of stable intermediates.In situdesilylation transiently leads to terminal arylazoacetylenes that undergo copper-catalyzed cycloadditions (CuAAC) with a diverse collection of organoazides. These include complex molecules derived from natural products or drugs, such as colchicine, taxol, tamiflu, and arachidonic acid. The arylazotriazoles display near-quantitative photoisomerization and long thermalZ-half-lives. Using the method, we introduce for the first time the design and synthesis of a diacetylene platform. It permits implementation of consecutive and diversity-oriented approaches linking two different conjugants to independently addressable acetylenes within a common photoswitchable azotriazole. This is showcased in the synthesis of several photoswitchable conjugates, with potential applications as photoPROTACs and biotin conjugates.

Structure–activity relationships of GPX4 inhibitor warheads

Direct inhibition of GPX4 requires covalent modification of the active-site selenocysteine. While phenotypic screening has revealed that activated alkyl chlorides and masked nitrile oxides can inhibit GPX4 covalently, a systematic assessment of potential electrophilic warheads with the capacity to inhibit cellular GPX4 has been lacking. Here, we survey more than 25 electrophilic warheads across several distinct GPX4-targeting scaffolds. We find that electrophiles with attenuated reactivity compared to chloroacetamides are unable to inhibit GPX4 despite the expected nucleophilicity of the selenocysteine residue. However, highly reactive propiolamides we uncover in this study can substitute for chloroacetamide and nitroisoxazole warheads in GPX4 inhibitors. Our observations suggest that electrophile masking strategies, including those we describe for propiolamide- and nitrile-oxide-based warheads, may be promising for the development of improved covalent GPX4 inhibitors.

Antibody-medicine conjugate targeting EGFR and preparation method and application thereof

The invention relates to an antibody-medicine conjugate targeting an EGFR. The antibody-medicine conjugate targeting the EGFR is characterized in that the antibody-medicine conjugate of a structure shown in a formula I or pharmaceutically-accepted salt or solvate is involved. According to a structural formula of the antibody-medicine conjugate targeting the EGFR, n represents the medicine-antibody proportion and is 3-5; R is O or CONH or NHCO; R is in para-position or meta-position; p is 1-6; m is 0-20. According to the antibody-medicine conjugate targeting the EGFR, based on a bis-ethylene sulfamide connection connexin technology, the antibody-medicine conjugate targeting the EGFR is synthesized for the first time. According to the antibody-medicine conjugate targeting the EGFR, internal sulphur-sulphur bonds of an antibody are broken and then bridged, the conjugate with good uniformity and DAR of about 4 can be obtained, and the antibody is wide in application range.

N-Phenyl-N-aceto-vinylsulfonamides as Efficient and Chemoselective Handles for N-Terminal Modification of Peptides and Proteins

A number of vinylsulfonamides were synthesized and screened to identify reagents that can be used to modify octreotide under biological pH and room temperature with improved efficiency. N-Phenyl-N-aceto-vinylsulfonamide exhibits higher reactivity and has emerged as an efficient reagent that has the ability to realize the selective modification of peptides and proteins at the N-terminus via aza-Michael addition. We showed that, after conjugation of peptides and proteins with the reagent containing a bioorthogonal functional group, the derivatives could be further labelled by functionalities, including fluorescent tags, modified drugs and polyethylene glycol (PEG) polymers without the need for prior treatment. Somatostatin, lysozyme, and RNaseA were selectively modified at the N-terminus, which illustrated the application of the method.

1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity

The emergence of multi- and extensively-drug resistant tubercular (MDR- and XDR-TB) strains of mycobacteria has limited the use of existing therapies, therefore new drugs are needed. Dihydrofolate reductase (DHFR) has recently attracted much attention as

2,4 SUBSTITUTED PYRIMIDINEDIAMINES FOR USE IN DISCOID LUPUS

no abstract published

Self-Assembled Magnetic Gold Catalysts from Dual-Functional Boron Clusters

A new class of core–shell magnetic gold nanocomposites is prepared in a raspberry-like fashion by the controlled supramolecular host–guest assembly of γ-cyclodextrins (γ-CDs) and boron clusters. In this work, Cs2[closo-B12H12], a fundamental boron cluster, can play a dual role in the preparation of highly monodispersed Au nanoparticles and in the immobilization of Au nanoparticles on the γ-CDs@Fe3O4 surface as an effective anchor. This facile and spontaneous supramolecular strategy allows for the control of the size and composition of the highly stable gold composites. Furthermore, the obtained AuNPs@Fe3O4 composites exhibit an excellent catalytic activity and recyclability for the selective reduction of nitroaromatics to their corresponding aniline compounds, and the fastest reaction can be achieved within 20 s with a high conversion and selectivity at room temperature, which is better than that obtained previously in studies on metal nanoparticle composites as catalysts.